Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 10/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15783238 | 0.84 | MAOA (0.41) | MAOAMAOBMGLLFAAHALDH1A1 | |
| SCHEMBL2639486 | 0.78 | MGLL (0.50) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL14587456 | 0.75 | MGLL (0.54) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL10699322 | 0.74 | MGLL (0.46) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL797328 | 0.72 | MGLL (0.62) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL23246173 | 0.70 | MAOA (0.37) | MAOAMAOBTP53AMY1ACYP19A1 | |
| SCHEMBL17070868 | 0.70 | MGLL (0.48) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL7560300 | 0.69 | — | — | |
| SCHEMBL16307837 | 0.69 | RGS4 (0.49) | MAOAMAOBAMY1A | |
| SCHEMBL17629426 | 0.68 | MGLL (0.59) | MGLLFAAHALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116603-B2 | RNA silencing nanozymes | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-10-15 | — | — | US | claimed |
| CN-116392580-A | Type 1 diabetes multi-antigen vaccine preparation and application thereof | 中国科学技术大学 | 2023-07-07 | — | — | CN | claimed |
| CN-115598340-A | Detection method for ultrasensitive fluorescence counting immunoassay by using biological orthogonal reaction immobilized bacteria | 南京大学（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-4045088-A1 | METHOD FOR THE PREPARATION OF POLYMERIC CARRIERS FOR PH- CONTROLLED DRUG RELEASE AND THEIR CONJUGATES WITH DRUGS | Ustav Makromolekularni Chemie AV CR, v.v.i. (CZ) | 2022-08-24 | — | — | EP | claimed |
| WO-2022093792-A1 | ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220131195-A1 | ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | claimed |
| US-20200388885-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| EP-0850920-B1 | Ionic conductive materials comprising salts of perfluorinated amides and uses thereof | CENTRE NAT RECH SCIENT (FR) | 2002-09-11 | — | — | EP | claimed |
| US-12269797-B2 | Bifunctional linker for bisconjugation, method of synthesis, and method of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) | 2025-02-27 | — | — | US | disclosed |
| CN-115192732-B | DNA toxic dimer compound and conjugate thereof | 成都百利多特生物药业有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| US-12115261-B2 | Block copolymer comprising hydrophilic first block, hydrophobic second block, and functional group capable of specifically binding to thiol | GI CELL, INC. (KR) | 2024-10-15 | — | — | US | disclosed |
| US-7179907-B2 | Antibiotic compounds | SOMALOGIC OPERATING CO. INC. | 2007-02-20 | — | — | US | disclosed |
| WO-2007018431-A2 | TRIAZOLE-CONTAINING RELEASABLE LINKERS AND CONJUGATES COMPRISING THE SAME | SYNTARGA B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| EP-0850920-B1 | Ionic conductive materials comprising salts of perfluorinated amides and uses thereof | CENTRE NAT RECH SCIENT (FR) | 2002-09-11 | — | — | EP | disclosed |
| EP-0946648-B1 | HARDENABLE ORGANOSILOXANE PRODUCTS | WACKER CHEMIE GMBH (DE) | 2000-07-05 | — | — | EP | disclosed |
| EP-0946648-A1 | HARDENABLE ORGANOSILOXANE PRODUCTS | Wacker-Chemie GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027163-A1 | HARDENABLE ORGANOSILOXANE PRODUCTS | WACKER-CHEMIE GMBH (DE) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064964-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | ABL1, BCR, CD47 | MAOA 4348/4885MAOB 4339/4885MGLL 4860/4885 |
| US-12269797-B2 | Bifunctional linker for bisconjugation, method of synthesis, and method of use | C1R, C9, FCGRT | MAOA 1657/4885MAOB 1572/4885MGLL 4558/4885 |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | MUSK, TFRC, SLC7A1 | MAOA 4624/4885MAOB 4069/4885MGLL 4852/4885 |
| US-20220131195-A1 | ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED LI-ION BATTERIES | SELENOI, SIK1, SIK2 | MAOA 2197/4885MAOB 2710/4885MGLL 3026/4885 |
| US-12171839-B2 | Antibody drug conjugates for ablating hematopoietic stem cells | BCR, ABL1, CD47 | MAOA 4253/4885MAOB 4257/4885MGLL 4849/4885 |
| US-12115261-B2 | Block copolymer comprising hydrophilic first block, hydrophobic second block, and functional group capable of specifically binding to thiol | TBCB, HSPA1B, FGB | MAOA 3626/4885MAOB 590/4885MGLL 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.